Thus, the studies of association of cytokine levels with CKD progression or death do not reflect natural history but residual risk despite the fact that optimised treatment and progression rates were consistent with those reported for the intervention arm (SGLT2I, GLP1RAs, and mineralocorticoid receptor antagonists (MRAs)) of recent clinical trials in patients with DKD [59,60,61]. Here, NR3C2 is linked to chronic kidney disease.